Related Experiment Video
Updated: Feb 24, 2026
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and
Carlos Alberto de Carvalho Fraga1, Lucyana Conceicao Farias2, Kimberly Marie Jones3
1Department of Medicine Universidade Federal de Alagoas, Arapiraca, Alagoas, Brazil.
Introduction:
The Renin-Angiotensin System (RAS) has emerged as being related to vascular disease. Recently the RAS has been associated with obesity, diabetes, and even cancer.
Objective:
This review and Bioinformatics analyses focuses on the investigation of Angiotensinconverting enzymes (ACE and ACE2) as therapeutical targets for Malignant Epithelial Neoplasia, specifically for Oral Squamous Cell Carcinoma (OSCC).
Conclusion:
The literature review and Bioinformatics analyses showed that ACE and ACE2 are interesting targets for OSCC treatment. Studies involving RAS and OSCC should be encouraged for experimental validation.
Insights
The Renin-Angiotensin System (RAS) shows potential as a therapeutic target for Oral Squamous Cell Carcinoma (OSCC). Angiotensin-converting enzymes (ACE and ACE2) are key targets for OSCC treatment, warranting further research.
Area of Science:
- Oncology
- Cardiovascular Research
- Biochemistry
Background:
- The Renin-Angiotensin System (RAS) is implicated in vascular diseases.
- Emerging evidence links RAS to metabolic disorders like obesity and diabetes, and to cancer development.
Purpose of the Study:
- To investigate Angiotensin-converting enzymes (ACE and ACE2) as potential therapeutic targets.
- Focus on Malignant Epithelial Neoplasia, specifically Oral Squamous Cell Carcinoma (OSCC).
Main Methods:
- Comprehensive literature review.
- Bioinformatics analyses to assess ACE and ACE2 roles in OSCC.
Main Results:
- ACE and ACE2 were identified as significant targets in the context of OSCC.
- Bioinformatics data supports the therapeutic relevance of targeting these enzymes.
Conclusions:
- ACE and ACE2 represent promising therapeutic targets for Oral Squamous Cell Carcinoma.
- Further experimental studies are recommended to validate the role of RAS in OSCC.
